Navigation Links
Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
Date:4/27/2009

COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of Santaris Pharma's efficient Drug Discovery Engine, the Company announced today the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.

Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe. The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1ÿ±, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.

"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."

http://www.santaris.com

Santaris Pharma (founded in 2003)
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
6. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
7. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
8. Helix BioPharma to Present at the BioFinance 2009 Conference
9. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
(Date:8/28/2014)... Florida State University research team has led to a ... white light, and convert photon energy directly to mechanical ... , Biwu Ma, associate professor in the Department of ... Engineering, created the molecule in a lab about a ... creation has many other unique capabilities. , For example, ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... ALISO VIEJO, Calif., May 5 ... Genomic Hybridization (CGH) using oligonucleotide arrays through a partnership ... abnormalities that are associated with over 270 genetic syndromes ... whole genome and mitochondrial array. The partnership with ...
... NEEDHAM, Mass., May 5 A new ... to improve both building systems performance and energy ... with much of the savings linked to low-cost modifications. ... Engineering, Inc. (EH&E), a leading Massachusetts-based environmental and ...
... HUBBARD, Ohio, May 5 NanoLogix, Inc. (Pink Sheets: ... technology at booth 749 during the 109th Annual ASM ... in Philadelphia May 17th - 21st. The ASM meeting ... NanoLogix will be Dr. Sergey Gazenko and CEO Bret ...
Cached Biology Technology:Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine 2New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 2NanoLogix Inc. to Exhibit at The American Society for Microbiology (ASM) General Meeting in Philadelphia; Announces Two New Patents 3
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... The support of peer groups and clinicians is ... according to recent University of Georgia research. , ... Athens-Clarke County area determined that role models for ... mothers of infants. , "Mothers who received that ... breastfeeding," said study co-author Alex Anderson, an associate ...
(Date:8/28/2014)... are good examples of complex systems. Their infrastructure ... water for cooling, transport to supply fuel, and ... in the network chain is interconnected with a ... A team of UK-based scientists has studied various ... findings have been published in EPJ B by ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2Breastfeeding study shows need for effective peer counseling programs 2Inter-dependent networks stress test 2
... Mediterranean Sea small animals have been discovered that live ... sulphides. Researchers writing in the open access journal ... (new members of the group Loricifera), showing that they ... of a complete absence of oxygen. Roberto Danovaro, ...
... 7, 2010) More than 1600 genetics researchers who use ... to study basic aspects of biology ranging from memory to ... underlie evolution, will be gathering in Washington, DC, for the ... Genetics Society of America, and beginning this evening at the ...
... women have poorer survival rates than their white ... radiation therapy following lumpectomy or mastectomy, UC Davis ... of surgery at UC Davis Cancer Center, determined ... breast cancer are less likely to receive radiation ...
Cached Biology News:First animals to live without oxygen discovered 2Drosophilists fly into DC for 51st Annual Drosophila Research Conference 2Disparities persist in outcomes for African-American women with advanced breast cancer 2
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ,• ... which exhibits very high activity in primer ... ensure the quality of the enzyme, each ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Taq DNA polymerase, 10,000U...
... 5 units/µL ,• High specific activity and ... an 'A' overhang ,• Processes ... high activity in primer extension and other ... of the enzyme, each lot has been ...
Biology Products: